Global Anticoagulant Market 2017-2021

抗凝血剤の世界市場2017-2021

◆タイトル:Global Anticoagulant Market 2017-2021
◆商品コード:IRTNTR12016
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年2月16日
◆ページ数:79
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、抗凝血剤の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、抗凝血剤の世界市場規模及び予測、用途別分析、薬剤種類別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

ABSTRACTAbout Anticoagulant Market
Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.

Technavio’s analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.

The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC

Technavio’s report, Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer HealthCare
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

[Other prominent vendors]
• Abbott Vascular
• Abiomed
• AtriCure
• Biosensors International
• Biotronik
• BioVentrix
• C. R. Bard

[Market driver]
• Increasing demand for NOACs
• For a full, detailed list, view our report

[Market challenge]
• Increasing cost of NOACs
• For a full, detailed list, view our report

[Market trend]
• Strategic alliance
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents

PART 01: Executive summary 

PART 02: Scope of the report 

Market overview 
Top-vendor offerings 

PART 03: Market research methodology 

Research methodology 
Economic indicators 

PART 04: Introduction 

Key market highlights 

PART 05: Disease overview 

PART 06: Pipeline analysis 

PART 07: Market landscape 

Market overview 
Five forces analysis 

PART 08: Market segmentation by ROA 

Oral anticoagulants 
Injectable anticoagulants 

PART 09: Market segmentation by drug class 
Factor Xa inhibitors 
DTIs 
Heparin 
Vitamin K antagonists 

PART 10: Market segmentation by application 

DVT 
PE 
AF 
Others 

PART 11: Geographical segmentation 

Global anticoagulant market in Americas 
Anticoagulant market in EMEA 
Anticoagulant market in APAC 

PART 12: Market drivers 

Increasing demand for NOACs 
Growing prevalence of coagulation disorders 
Increase in hip and knee surgeries 

PART 13: Impact of drivers 

PART 14: Market challenges 

Increasing cost of NOACs 
Lack of antidotes in the market for NOACs 
Patent expiry: a threat to market 

PART 15: Impact of drivers and challenges 

PART 16: Market trends 

Strategic alliance 
Increasing focus toward emerging economies 
Patient assistance programs 

PART 17: Vendor landscape 

Competitive scenario 
Other prominent vendors 

PART 18: Key vendor analysis 

Bayer HealthCare 
Boehringer Ingelheim 
Bristol-Myers Squibb 
Daiichi Sankyo 
Johnson & Johnson 
Sanofi 

PART 19: Appendix 

List of abbreviations 

PART 20: Explore Technavio 

[List of Exhibits]

Exhibit 01: Product offerings 

Exhibit 02: Process of blood coagulation 

Exhibit 03: Mechanism of action (MoA) of anticoagulant 

Exhibit 04: Key customer segments of global anticoagulant market 

Exhibit 05: Pipeline analysis 2016 

Exhibit 06: Key pipeline molecules 

Exhibit 07: Global anticoagulant market overview 

Exhibit 08: Global anticoagulant market 2016-2021 ($ billions) 

Exhibit 09: Five forces analysis 

Exhibit 10: Segmentation of anticoagulant market based on ROA 

Exhibit 11: Market share of anticoagulant based on ROA 2016 

Exhibit 12: Types of heparin 

Exhibit 13: Segmentation of anticoagulant market based on drug class 

Exhibit 14: Market share of anticoagulant based on drug class 2016 

Exhibit 15: Types of factor Xa inhibitors based on MOA 

Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions) 

Exhibit 17: Types of DTIs based on MOA 

Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions) 

Exhibit 19: Global heparin market 2016-2021 ($ billions) 

Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions) 

Exhibit 21: Market segmentation by application 

Exhibit 22: Market segmentation of anticoagulant based on application 

Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions) 

Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions) 

Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions) 

Exhibit 26: Impact of drivers 

Exhibit 27: Patents to expire over forecast period 

Exhibit 28: Impact of drivers and challenges 

Exhibit 29: Competitive structure analysis of global anticoagulant market 2016 

Exhibit 30: Competitive analysis of global anticoagulant market 

Exhibit 31: Market share analysis 2016 

Exhibit 32: Competitive landscape analysis 2016 

Exhibit 33: Bayer HealthCare: Key highlights 

Exhibit 34: Bayer HealthCare: Strength assessment 

Exhibit 35: Bayer HealthCare: Strategy assessment 

Exhibit 36: Bayer HealthCare: Opportunity assessment 

Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions) 

Exhibit 38: Boehringer Ingelheim: Key highlights 

Exhibit 39: Boehringer Ingelheim: Strength assessment 

Exhibit 40: Boehringer Ingelheim: Strategy assessment 

Exhibit 41: Boehringer Ingelheim: Opportunity assessment 

Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions) 

Exhibit 43: Bristol-Myers Squibb: Highlights 

Exhibit 44: Bristol-Myers Squibb: Strength assessment 

Exhibit 45: Bristol-Myers Squibb: Strategy assessment 

Exhibit 46: Bristol-Myers Squibb: Opportunity assessment 

Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions) 

Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015 

Exhibit 49: Daiichi Sankyo: Key highlights 

Exhibit 50: Daiichi Sankyo: Strength assessment 

Exhibit 51: Daiichi Sankyo: Strategy assessment 

Exhibit 52: Daiichi Sankyo: Opportunity assessment 

Exhibit 53: Johnson & Johnson: Strength assessment 

Exhibit 54: Johnson & Johnson: Strategy assessment 

Exhibit 55: Johnson & Johnson: Opportunity assessment 

Exhibit 56: Sanofi: Key highlights 

Exhibit 57: Sanofi: Strength assessment 

Exhibit 58: Sanofi: Strategy assessment 

Exhibit 59: Sanofi: Opportunity assessment 

Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions) 

Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016  



【資料のキーワード】

抗凝血剤

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[抗凝血剤の世界市場2017-2021] (Global Anticoagulant Market 2017-2021 / IRTNTR12016)販売に関する免責事項
[抗凝血剤の世界市場2017-2021] (Global Anticoagulant Market 2017-2021 / IRTNTR12016)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆